Clinical Trial Update: Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating human umbilical cord blood RegeneCyte infusion for post-COVID syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• REGENECYTE (umbilical cord blood infusion)

Snippet

Sponsor: StemCyte, Inc. | Conditions: Long COVID, Post-COVID Syndrome | Phase 2 | Status: COMPLETED